Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and increased supply chain flexibility, to pharmaceutical customers globally
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Hovione has once again solidified its position as a top employer.